Paclitaxel sensitizes multidrug resistant cells to radiation

Anti-Cancer Drugs

Volumn 7, Issue 2, 1996, Pages 182-188

  Mote, Patricia A ^a   Davey, Mary W ^a   Davey, Ross A ^b   Oliver, Lyn ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

multidrug resistance; P glycoprotein; paclitaxel (taxol; radiation

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL STRAIN HL 60; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RADIATION; RADIOSENSITIZATION;

EID: 0029879415     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199602000-00006     Document Type: Article

References (28)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
2. Benchimol S, Ling V. P-glycoprotein and tumor progression. J Natl Cancer Inst 1994; 86: 814-5.
3. Cole SP, Bhardwaj G, Gerlach JH, et al., Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
4. Guchelaar H-J, Ten Napel CHH, de Vries EGE, Mulder NH. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol 1994; 6: 40-8.
5. O'Shaughnessy JA, Cowan KH. Current status of paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 1994; 33: 27-37.
6. Rowinsky EK. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 1994; 28: S18-S22.
7. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-59.
8. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 2682-6.
9. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of taxol as a potential radiation sensitizer. Cancer 1993; 71: 3774-8.
10. Geard CR, Jones JM, Schiff PB. Taxol and radiation. Monogr Natl Cancer Inst 1993; 15: 89-94.
11. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (taxol). Int J Radiat Oncol Biol Phys 1994; 29: 559-64.
12. Steren A, Sevin B-U, Perras J, et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 1993; 48: 252-8.
13. Steren A, Sevin B-U, Perras J, et al. Taxol as a radiation sensitizer: a flow cytometric study. Gynecol Oncol 1993; 50: 89-93.
14. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation Cancer Res 1992; 52: 3495-7.
15. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613-7.
16. Minarik L, Hall EJ. Taxol in combination with acute and low dose rate irradiation. Radiother Oncol 1994; 32: 124-8.
17. Su GMI, Davey MW, Davey RA, Kidman AD. Development of extended multidrug resistance in HL60 promyelocytic leukemia cells. Br J Haematol 1994; 88: 566-74.
18. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with promyelocytic leukemia. Blood 1979; 54: 713-33.
19. Marks DC, Belov L, Davey MW, Davey RA, Kidman AD. The MTT cell viability assay for cytotoxicity testing in multidrug resistant human leukemic cells. Leukemia Res 1992; 16: 1165-73.
20. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mithcell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensivity. Cancer Res 1987; 47: 943-6.
21. Rodriguez M, Sevin BU, Perras J, et al. Paclitaxel - a radiation sensitizer of human cervical cancer cells. Gynecol Oncol 1995; 57: 165-9.
22. Stromberg JS, Lee YJ, Armour EP, Martinez AA, Corry PM. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 1995; 75: 2262-8.
23. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase 1 clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486-93.
24. Webster L, Linsenmeyer M, Millward M, Motion C, Bishop J, Woodcock D. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug resistant phenotype. J Natl Cancer Inst 1993; 85: 1685-90.
25. Woodcock DM, Jefferson S, Linsenmeyer ME, et al. Reversal of multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990; 50: 4199-203.
26. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994; 54: 4355-61.
27. Roberts JR, Rowinsky EK, Donehower RC, Robertson J, Allison DC. Demonstration of the cell cycle positions of taxol induced 'asters' and 'bundles' by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiagraphic labelling of taxol-sensitive and resistant cells. J Histochem Cytochem 1989; 37: 1659-65.
28. Ball RL, Carney DH, Albrecht T. Taxol inhibits stimulation of cell DNA synthesis by human cytomegalovirus. Exp Cell Res 1990; 191: 37-44.